Clinical trial
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following…
NCT00489970 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00489970 |
|---|---|
| Title | Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 |
| Official title | Persistence Study of GSK Biologicals' Tdap Vaccine (776423), 1, 3, 5 and 9 Years Following Administration as a Single Dose in NCT00346073 Study and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acellular Pertussis, Tetanus, Diphtheria |
| Intervention type | Biological, Procedure |
| Interventions | Taking of blood samples, Boostrix, Adacel |
| Enrollment | 1,954 |
| Start date | Jun 1, 2007 |
| Primary completion | Sep 1, 2011 |
| Completion | Mar 1, 2016 |
| First posted | Jun 22, 2007 |
| Last update posted | May 1, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: